Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases
Serplulimab in Combination With Regorafenib and Hepatic Artery Bicarbonate Infusion for Third-line Treatment in Patients With Colorectal Cancer and Liver Metastases: a Single-center, Single-arm, Phase 2 Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Ying Yuan
- Phone Number: +86-13858193601
- Email: yuanying1999@zju.edu.cn
Study Contact Backup
- Name: Shanshan Weng
- Phone Number: +86-13758118823
- Email: 2310053@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- The Second Affiliated Hospital of Medical College of Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 or above, male or female;
- Patients with colorectal cancer and liver metastases who strictly conform to the clinical diagnostic criteria of "Chinese Guidelines for Diagnosis and Treatment of Colorectal Cancer (2020 Edition)" or who have been confirmed by histopathology or cytology;
- At least 1 measurable intrahepatic lesion;
- Child-Pugh liver function rating: A or good B (≤7 points) ;
- No local treatment including radiotherapy, surgical excision and ablation was performed before interventional therapy;
- No other malignant tumors;
- ECOG score within one week before enrollment: 0-1;
- Predicted survival ≥24 weeks;
- The major organs are functioning normally; the following criteria are met: Blood examination: a) HB≥90 g/L;b) ANC≥1.5×109/L;c) PLT≥80×109/L; Biochemical examination: a) ALB ≥29 g/L;b) ALT and AST<5ULN;c) TBIL ≤1.5ULN;d) Creatinine≤1.5ULN;(Only one of the two measures of albumin and bilirubin in the Child-Pugh rating can be a score of 2); Thyroid function tests are within normal range;
- Women of childbearing age must already be using reliable contraception or have had a pregnancy test (serum or urine) with negative results within 7 days prior to inclusion and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last test drug administration;
- The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up;
Exclusion Criteria:
- There is a contraindication of anti-PD-1 monoclonal antibody therapy;
- With other uncured malignancies, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ;
- Patients who are preparing for an organ transplant or have had an organ transplant in the past;
- Ascites with clinical symptoms that require therapeutic abdominal puncture or drainage, or Child-Pugh score > 2;
- Patients with high blood pressure (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg) who cannot be reduced to the normal range by antihypertensive medication;
- Patients with grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450 ms for males and 470 ms for females); A history of symptomatic ischemic or hemorrhagic cerebrovascular disease;
- Having multiple factors that affect oral medication (such as inability to swallow, chronic diarrhea, and intestinal obstruction, which significantly affects drug administration and absorption);
- Patients with a history of gastrointestinal bleeding or a definite tendency to gastrointestinal bleeding within the past 6 months, such as esophageal varicose veins with bleeding risk, locally active ulcer lesions, stool occult blood ≥ (++), should not be included in the group; If fecal occult blood (+), gastroscopy is required;
- Had an abdominal fistula, gastrointestinal perforation, or abdominal abscess in the 28 days prior to joining the study;
- Patients with abnormal coagulation function (INR > 1.5 or prothrombin time (PT) > ULN+4 seconds) who are prone to bleeding or are receiving thrombolytic or anticoagulant therapy;
- Patients with central nervous system metastases or known brain metastases;
- Patients with past and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, and severe impairment of lung function;
- Urine routine showed urine protein ≥++ or confirmed 24 hours urine protein quantity > 1.0 g;
- Severe thyroid disease cannot be controlled by treatment;
- Rheumatic or autoimmune diseases, and immunosuppressant or high-dose hormone therapy after organ transplantation;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Serplulimab in combination with Regorafenib and hepatic artery bicarbonate infusion
Serplulimab: once every two weeks; Regorafenib: from the first day to the 21th day; hepatic artery bicarbonate infusion: once every four weeks
|
Serplulimab: once every two weeks; Regorafenib: from the first day to the 21st day
hepatic artery bicarbonate infusion: once every four weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate
Time Frame: From Baseline to disease progress, up to 18 months
|
Objective Response Rate was defined as the proportion of patients with a best objective response of complete response (CR) or partial response (PR) according to RECIST criteria (version 1.1).
|
From Baseline to disease progress, up to 18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events and Serious Adverse Events
Time Frame: From Baseline to primary completion date, about 2 years
|
Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0.
|
From Baseline to primary completion date, about 2 years
|
|
Progression free survival
Time Frame: From Baseline to primary completion date, about 2 years
|
Progression-free survival is defined as the time from enrollment to the first documented disease progression according to RECIST version 1.1, or to death from any cause, whichever occurred first
|
From Baseline to primary completion date, about 2 years
|
|
Overal survival
Time Frame: From Baseline to primary completion date, about 5 years
|
Time from randomization to death (from any cause)
|
From Baseline to primary completion date, about 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Ying Yuan, The Second Affiliated Hospital of Medical College of Zhejiang University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Liver Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasm Metastasis
- Liver Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- 2023-034 (Other Identifier: Meriter IRB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.